Your browser doesn't support javascript.
Characterization of antimicrobial use and co-infections among hospitalized patients with COVID-19: a prospective observational cohort study.
Lingscheid, Tilman; Lippert, Lena J; Hillus, David; Kruis, Tassilo; Thibeault, Charlotte; Helbig, Elisa T; Tober-Lau, Pinkus; Pfäfflin, Frieder; Müller-Redetzky, Holger; Witzenrath, Martin; Zoller, Thomas; Uhrig, Alexander; Opitz, Bastian; Suttorp, Norbert; Kramer, Tobias S; Sander, Leif E; Stegemann, Miriam S; Kurth, Florian.
  • Lingscheid T; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Lippert LJ; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
  • Hillus D; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Kruis T; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
  • Thibeault C; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Helbig ET; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
  • Tober-Lau P; Labor Berlin Charité Vivantes GmbH, Mikrobiologie and Hygiene, Sylter Str. 2, 13353, Berlin, Germany.
  • Pfäfflin F; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Müller-Redetzky H; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
  • Witzenrath M; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Zoller T; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
  • Uhrig A; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Opitz B; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
  • Suttorp N; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Kramer TS; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
  • Sander LE; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Stegemann MS; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
  • Kurth F; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Infection ; 50(6): 1441-1452, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-1787897
ABSTRACT

PURPOSE:

To investigate antimicrobial use and primary and nosocomial infections in hospitalized COVID-19 patients to provide data for guidance of antimicrobial therapy.

METHODS:

Prospective observational cohort study conducted at Charité-Universitätsmedizin Berlin, including patients hospitalized with SARS-CoV-2-infection between March and November 2020.

RESULTS:

309 patients were included, 231 directly admitted and 78 transferred from other centres. Antimicrobial therapy was initiated in 62/231 (26.8%) of directly admitted and in 44/78 (56.4%) of transferred patients. The rate of microbiologically confirmed primary co-infections was 4.8% (11/231). Although elevated in most COVID-19 patients, C-reactive protein and procalcitonin levels were higher in patients with primary co-infections than in those without (median CRP 110 mg/l, IQR 51-222 vs. 36, IQR 11-101, respectively; p < 0.0001). Nosocomial bloodstream and respiratory infections occurred in 47/309 (15.2%) and 91/309 (29.4%) of patients, respectively, and were associated with need for invasive mechanical ventilation (OR 45.6 95%CI 13.7-151.8 and 104.6 95%CI 41.5-263.5, respectively), extracorporeal membrane oxygenation (OR 14.3 95%CI 6.5-31.5 and 16.5 95%CI 6.5-41.6, respectively), and haemodialysis (OR 31.4 95%CI 13.9-71.2 and OR 22.3 95%CI 11.2-44.2, respectively). The event of any nosocomial infection was significantly associated with in-hospital death (33/99 (33.3%) with nosocomial infection vs. 23/210 (10.9%) without, OR 4.1 95%CI 2.2-7.3).

CONCLUSIONS:

Primary co-infections are rare, yet antimicrobial use was frequent, mostly based on clinical worsening and elevated inflammation markers without clear evidence for co-infection. More reliable diagnostic prospects may help to reduce overtreatment. Rates of nosocomial infections are substantial in severely ill patients on organ support and associated with worse patient outcome.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cross Infection / Coinfection / COVID-19 / COVID-19 Drug Treatment / Anti-Infective Agents Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Infection Year: 2022 Document Type: Article Affiliation country: S15010-022-01796-w

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Cross Infection / Coinfection / COVID-19 / COVID-19 Drug Treatment / Anti-Infective Agents Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Infection Year: 2022 Document Type: Article Affiliation country: S15010-022-01796-w